1-16 of 16
Robert A. Copeland
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract SY11-02: Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics

Robert A. Copeland, Jennifer Castro, Matthew H. Daniels, Deepali Gotur, Young-Tae Lee, Shihua Yao, David Brennan, Brian T. Johnston, Monique Laidlaw, Sunaina Pai, Jie Wu, Rishabh Bansal, Anugraha Raman, Shane M. Buker, Julie Liu, E. Allen Sickmier, Kevin Knockenhauer, Chuang Lu, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Jason A. Sager
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): SY11-02.
https://doi.org/10.1158/1538-7445.AM2024-SY11-02
Published: 05 April 2024
View article titled, Abstract SY11-02: Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics
Journal Articles

Abstract 520: circBRIP1 RNA as a non-invasive target engagement pharmacodynamic biomarker for DHX9 inhibition

David Brennan, Jennifer Castro, Matthew H. Daniels, Monique Laidlaw, Chuang Lu, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Jason A. Sager, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 520.
https://doi.org/10.1158/1538-7445.AM2024-520
Published: 22 March 2024
View article titled, Abstract 520: circBRIP1 RNA as a non-invasive target engagement pharmacodynamic biomarker for DHX9 inhibition
Journal Articles

Abstract 3337: Inhibition of KIF18A leads to mitotic arrest and robust anti-tumor activity in chromosomally instable tumors

Maureen S. Lynes, Sanjoy Khan, Taylor Hotz, Brian A. Sparling, Mary-Margaret Zablocki, Deepali Gotur, P Ann Boriack-Sjodin, Kenneth W. Duncan, Stephen J. Blakemore, Serena J. Silver, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3337.
https://doi.org/10.1158/1538-7445.AM2024-3337
Published: 22 March 2024
View article titled, Abstract 3337: Inhibition of KIF18A leads to mitotic arrest and robust anti-tumor activity in chromosomally instable tumors
Journal Articles

Abstract 3908: DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2

Jennifer B. Castro, Matthew H. Daniels, Sunaina Nayak, Monique Laidlaw, David Brennan, Brian T. Johnston, Jie Wu, Anugraha Raman, Chuang Lu, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Jason A. Sager, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3908.
https://doi.org/10.1158/1538-7445.AM2024-3908
Published: 22 March 2024
View article titled, Abstract 3908: DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2
Journal Articles

Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2

Jennifer Castro, Matthew H. Daniels, Sunaina Pai, Monique Laidlaw, Jie Wu, David Brennan, Brian T. Johnston, Anugraha Raman, Chuang Lu, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Jason A. Sager, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2024) 84 (1_Supplement): PR003.
https://doi.org/10.1158/1538-7445.DNAREPAIR24-PR003
Published: 09 January 2024
View article titled, Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2
Journal Articles

Abstract 1136: Targeting DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer

Jennifer Castro, Matthew H. Daniels, Chuang Lu, David Brennan, Deepali Gotur, Young-Tae Lee, Kevin Knockenhauer, April Case, Jie Wu, Shane M. Buker, Julie Liu, Brian A. Sparling, E. Allen Sickmier, Stephen J. Blakemore, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Scott Ribich, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1136.
https://doi.org/10.1158/1538-7445.AM2023-1136
Published: 04 April 2023
View article titled, Abstract 1136: Targeting DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer
Journal Articles

Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT

Christine R. Klaus, Jeffrey A. Keats, Jesse J. Smith, Richard Chesworth, Robert A. Copeland, Scott Ribich, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1944.
https://doi.org/10.1158/1538-7445.AM2017-1944
Published: 01 July 2017
View article titled, Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT
Journal Articles

Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical models

Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R. Grassian, Igor Feldman, Maria Roche, Peter Ho, Dorothy Brach, Alejandra Raimondi, Robert A. Copeland, Richard Chesworth, Jesse J. Smith, Scott A. Ribich
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3345.
https://doi.org/10.1158/1538-7445.AM2017-3345
Published: 01 July 2017
View article titled, Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: <em>In vitro</em> and <em>in vivo</em> preclinical models
Journal Articles

Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models

Allison E. Drew, Vinny Motwani, John E. Campbell, Cuyue Tang, Jesse J. Smith, Richard Chesworth, Robert A. Copeland, Alejandra Raimondi, Scott Ribich
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5060.
https://doi.org/10.1158/1538-7445.AM2017-5060
Published: 01 July 2017
View article titled, Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
Journal Articles

Abstract 2701: Characterization of acquired EPZ-5676 resistance in cell line models of MLL rearranged leukemia

Scott R. Daigle, Carly T. Campbell, Nigel J. Waters, Edward J. Olhava, Robert A. Copeland, Stephen J. Blakemore, Roy M. Pollock, Jesse J. Smith
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2701.
https://doi.org/10.1158/1538-7445.AM2015-2701
Published: 01 August 2015
View article titled, Abstract 2701: Characterization of acquired EPZ-5676 resistance in cell line models of MLL rearranged leukemia
Journal Articles

Abstract 2144: Kinetic mechanism of the lysine methyltransferase SMYD3 using MAP3K2 protein substrate

Thomas V. Riera, Tim J. Wigle, Jodi Gureasko, P. Ann Boriack-Sjodin, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2144.
https://doi.org/10.1158/1538-7445.AM2015-2144
Published: 01 August 2015
View article titled, Abstract 2144: Kinetic mechanism of the lysine methyltransferase SMYD3 using MAP3K2 protein substrate
Journal Articles

Abstract 97: CARM1 preferentially methylates H3R17 over H3R26 through a random kinetic mechanism

Suzanne L. Jacques, Katrina P. Aquino, Jodi Gureasko, P Ann Boriack-Sjodin, Robert A. Copeland, Thomas V. Riera
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 97.
https://doi.org/10.1158/1538-7445.AM2015-97
Published: 01 August 2015
View article titled, Abstract 97: CARM1 preferentially methylates H3R17 over H3R26 through a random kinetic mechanism
Journal Articles

Abstract 5383: DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical models of MLL-rearranged leukemia

Christine R. Klaus, Scott R. Daigle, Vivek Chopra, Jeffrey A. Keats, Carly T. Campbell, Dorothy Iwanowicz, Edward J. Olhava, Margaret P. Scott, Roy M. Pollock, Robert A. Copeland, Jesse J. Smith, Jorge DiMartino, Stephen J. Blakemore, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5383.
https://doi.org/10.1158/1538-7445.AM2015-5383
Published: 01 August 2015
View article titled, Abstract 5383: DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical models of MLL-rearranged leukemia
Journal Articles

Abstract 104: ATF7IP does not alter the substrate specificity of the lysine methyltransferase SETDB1

Aravind Basavapathruni, Jodi Gureasko, Margaret Porter Scott, P. Ann Boriack-Sjodin, Timothy J. Wigle, Thomas V. Riera, Robert A. Copeland
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 104.
https://doi.org/10.1158/1538-7445.AM2015-104
Published: 01 August 2015
View article titled, Abstract 104: ATF7IP does not alter the substrate specificity of the lysine methyltransferase SETDB1
Journal Articles

Abstract SY08-01: Protein methyltransferases as a target class for cancer drug discovery

Robert A. Copeland
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): SY08-01.
https://doi.org/10.1158/1538-7445.AM2011-SY08-01
Published: 15 April 2011
View article titled, Abstract SY08-01: Protein methyltransferases as a target class for cancer drug discovery
Journal Articles

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Nelson Rhodes, Dirk A. Heerding, Derek R. Duckett, Derek J. Eberwein, Victoria B. Knick, Timothy J. Lansing, Randy T. McConnell, Tona M. Gilmer, Shu-Yun Zhang, Kimberly Robell, Jason A. Kahana, Robert S. Geske, Elena V. Kleymenova, Anthony E. Choudhry, Zhihong Lai, Jack D. Leber, Elisabeth A. Minthorn, Susan L. Strum, Edgar R. Wood, Pearl S. Huang, Robert A. Copeland, Rakesh Kumar
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2366–2374.
https://doi.org/10.1158/0008-5472.CAN-07-5783
Published: 01 April 2008
View article titled, Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Open the PDF for Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity in another window
Includes: Supplementary data